Upgrade to SI Premium - Free Trial

iBio receives Australian approval for Phase 1 trial of IBIO-600

April 8, 2026 7:00 AM
iBio Inc. (NASDAQ: IBIO) received regulatory clearance from Australia's Therapeutic Goods Administration and ethics approval from a Human Research Ethics ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA